Inhibitory effects of transforming growth factor-beta1 pretreatment on experimental pulmonary metastasis of MCS-1 Chinese hamster mesenchymal chondrosarcoma cells

• Published in: Tohoku journal of experimental medicine Vol. 187; no. 3; pp. 203 - 213
• Main Authors: Fujisawa, N, Sato, N L, Motoyama, T I
• Format: Journal Article
• Language: English
• Published: Japan 1999
• Subjects: Animals; Bone Neoplasms - drug therapy; Bone Neoplasms - pathology; Cattle; Chondrosarcoma, Mesenchymal - drug therapy; Chondrosarcoma, Mesenchymal - pathology; Cricetinae; Female; Lung Neoplasms - prevention & control; Lung Neoplasms - secondary; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Transforming Growth Factor beta - administration & dosage; Transplantation, Heterologous
• ISSN: 0040-8727; 1349-3329
• DOI: 10.1620/tjem.187.203

Recent studies have suggested that transforming growth factor(TGF)-beta1 acts as a multifunctional regulator of cell growth, and also modifies tumor progression and metastasis. In the present study, we investigated the effects of TGF-beta1 on the proliferation and experimental pulmonary metastasis of MCS-1. MCS-1 are undifferentiated type cloned tumor cells established from a mesenchymal chondrosarcoma which spontaneously occurred in the soft tissue of a female Chinese hamster. MCS-1 cells were pretreated with TGF-beta1 (0, 0.05, 0.5, 2, 10 ng/ml) for 72 hours in a medium containing 1% fetal bovine serum, then tested for in vitro growth by the MTT method, in vivo growth by subcutaneous inoculation into athymic nude mice (1 x 10(6) cells/mouse) and experimental pulmonary metastasis by injection into the lateral tail vein of athymic nude mice (5 x 10(4) cells/mouse). TGF-beta1 significantly inhibited in vitro growth of MCS-1, depending on its concentrations, and also experimental metastasis with maximal inhibition at 0.5 or 2 ng/ml treatment compared to untreated controls. TGF-beta1, however, was ineffective for in vivo subcutaneous growth of MCS-1. These results indicated that TGF-beta1 might be an inhibitor of metastasis of mesenchymal chondrosarcomas including other types of non-epitherial cartilage or bone formation tumors.